Published: Mon, April 16, 2018
Research | By Jody Lindsey

Clovis Oncology (CLVS) Downgraded by BidaskClub to Strong Sell

Finally, WallachBeth Capital boosted their price target on shares of Clovis Oncology from $22.00 to $49.00 and gave the company a hold rating in a research report on Wednesday, December 21st. Over the last quarter, insiders have sold 19,500 shares of company stock worth $1,156,455.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The stock had a trading volume of 738,870 shares, compared to its average volume of 1,168,992. About 686,060 shares traded. (NASDAQ:CLVS). Trust Department Mb Bancorporation N A has invested 0% in Clovis Oncology, Inc. CLVS underperformed the S&P 500 by 32.98%. 806 were reported by Qs Invsts Limited Liability Co. Following the sale, the director now owns 12,118 shares in the company, valued at $744,893.46. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping the Zacks' consensus estimate of ($1.29) by $0.25. Hancock Hldg Co now has $4.53B valuation. Novo Nordisk A/S (NYSE:NVO) has risen 42.07% since April 14, 2017 and is uptrending. It has outperformed by 30.52% the S&P500. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 15, 2017 and is downtrending. This year's EPS analyst estimate is anticipated to be $-1.34. On Tuesday, February 27 the stock has "Overweight" rating by Barclays Capital. Stifel Nicolaus lowered their price objective on shares of Clovis Oncology from $125.00 to $110.00 and set a buy rating on the stock in a research note on Tuesday, February 27th. The stock has "Outperform" rating by Credit Suisse on Wednesday, September 21. The rating was maintained by SunTrust on Friday, April 6 with "Buy". The stock has "Neutral" rating by Bank of America on Wednesday, September 6. On Thursday, February 22 Evercore upgraded Clovis Oncology, Inc. On Wednesday, November 15 the rating was maintained by Leerink Swann with "Buy". UBS maintained The Procter & Gamble Company (NYSE:PG) on Monday, October 26 with "Neutral" rating. On Thursday, November 2 the stock of Clovis Oncology, Inc.

Big Money Sentiment decreased to 1.05 in 2017 Q4. Its down 0.39, from 1.44 in 2017Q3. The ratio fall due to CLVS positioning: 35 sold and 69 reduced. 31 funds opened positions while 78 raised stakes. Citigroup Inc accumulated 59,143 shs. Macquarie Group Limited has 0.06% invested in The Procter & Gamble Company (NYSE:PG) for 396,481 shares. (NASDAQ:CLVS). Metropolitan Life Insur owns 14,138 shs. Texas-based Qcm Cayman has invested 1.04% in Clovis Oncology, Inc. Glenmede Tru Na reported 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) for 3,277 shares. Finally, Greenwood Capital Associates LLC lifted its holdings in shares of Clovis Oncology by 21.6% during the 4th quarter. (NASDAQ:CLVS). Birchview LP invested in 0.2% or 5,000 shares. Jolley Asset Mngmt holds 0.19% in The Procter & Gamble Company (NYSE:PG) or 3,186 shares. Federated Pa reported 16,000 shs. The Illinois-based Wolverine Asset Management Llc has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) for 6,475 shares. 34,700 were accumulated by Gabelli Com Invest Advisers. Axa accumulated 15,700 shares.

Moto G6 Plus spotted on Geekbench before public launch
Last week , we saw some renders of all three phones and live images of the Moto G6 Play that pretty much confirm their designs. However, as is the case with most launches, there have been a bunch of leaks and revelations ahead of the April 19 event.

Clovis Oncology, Inc. registered $1.37 million net activity with 0 insider buys and 6 sales since October 16, 2017. (NASDAQ:CLVS) shares were sold by SPICKSCHEN THORLEF. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 15th. SunTrust Banks increased their price target on shares of Clovis Oncology to $90.00 and gave the company a "buy" rating in a report on Monday, April 9th. Therefore 47% are positive. SCANA had 34 analyst reports since August 15, 2015 according to SRatingsIntel. On Friday, March 23 the stock of Clovis Oncology, Inc. As per Tuesday, November 17, the company rating was downgraded by Goldman Sachs. The company was maintained on Thursday, July 13 by Stifel Nicolaus. The rating was upgraded by HSBC on Wednesday, August 31 to "Hold". Wood maintained the shares of HBHC in report on Friday, April 8 with "Market Perform" rating.

Among 25 analysts covering Proctor & Gamble (NYSE:PG), 12 have Buy rating, 1 Sell and 12 Hold. On Friday, March 23 the company was maintained by RBC Capital Markets. The stock of Hancock Holding Company (NASDAQ:HBHC) has "Buy" rating given on Friday, January 19 by Piper Jaffray.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It improved, as 15 investors sold HBHC shares while 70 reduced holdings. (NASDAQ:CLVS). State Of Wisconsin Investment Board stated it has 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Bourgeon Capital Mgmt Ltd Limited Liability Company has 9,750 shs for 0.36% of their capital. Pnc Fin Services Gp reported 54,298 shares. Prudential stated it has 842,862 shares. Fin Counselors holds 0.1% or 57,219 shares. 1,060 are held by Hanseatic Management Service. Alliancebernstein Limited Partnership reported 0.05% stake. Jacobs Levy Equity reported 0.13% stake. Swiss Bankshares holds 79,050 shares. Wells Fargo And Communication Mn holds 0.01% of its portfolio in Hancock Holding Company (NASDAQ:HBHC) for 930,639 shares.

Like this: